Finanzen von Jupiter Neurosciences Inc (JUNS)JUNSJupiter Neurosciences Inc

Jupiter Neurosciences Inc (JUNS) generates its revenue primarily from Premium Nutritional Supplements, which accounts for 100.0% of total sales, equivalent to $18.65K. Understanding this concentration is critical for investors evaluating how JUNS navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Jupiter Neurosciences Inc maintains a gross margin of 86.88%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -11313.45%, while the net margin is -9380.89%. These profitability ratios, combined with a Return on Equity (ROE) of -1888.70%, provide a clear picture of how effectively JUNS converts its operational activities into shareholder value.

In the context of the broader market, JUNS competes directly with industry leaders such as EOCN and MBIO. With a market capitalization of $3.00M, it holds a leading position in the sector. When comparing efficiency, JUNS's gross margin of 86.88% stands against EOCN's N/A and MBIO's N/A. Such benchmarking helps identify whether Jupiter Neurosciences Inc is trading at a premium or discount relative to its financial performance.

The company's financial performance shows a net loss of $2.27 million in Q2 2026, with a gross margin of 86.88%, indicating some operational efficiency but overall financial instability.